Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
MRTX/Financials
Wall Street · Earnings · Institutional Sentiment
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Mirati Therapeutics, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | -3.1900 | -4.940 | 12 | 2 | -98 | -176 | -102 | -176 | -196 | -184 | 21 | 35 |
| 2020 | -5.6700 | -8.070 | 3 | 15 | -212 | -354 | -222 | -357 | -404 | -365 | 42 | 83 |
| 2021 | -7.9400 | -10.420 | 13 | 21 | -357 | -468 | -369 | -458 | -668 | -461 | 83 | 120 |
| 2022 | -11.2100 | -12.817 | 72 | 27 | -581 | -737 | -573 | -618 | -1,081 | -619 | 136 | - |
| 2023 | -13.1800 | -11.810 | 12 | 65 | -740 | -729 | -759 | -672 | -759 | -673 | 239 | - |
| 2024 | - | -10.252 | - | 180 | - | -696 | - | -180 | - | -180 | - | - |
| 2025 | - | -8.371 | - | 316 | - | -585 | - | -316 | - | -316 | - | - |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Mirati Therapeutics, Inc. can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$58.70